Diabetes mellitus Posts - Page 11 of 108 on Medivizor
Navigation Menu

Diabetes mellitus Posts on Medivizor

Can Vitamin B12 improve nerve function in patients with diabetes and nerve dysfunction?

Can Vitamin B12 improve nerve function in patients with diabetes and nerve dysfunction?

Posted by on Apr 11, 2021 in Diabetes mellitus | 0 comments

In a nutshell This study looked at the effectiveness of vitamin B12 in people with type 2 diabetes (T2D) and loss of nerve function. It found that the vitamin improved pain, sensation, and quality of life in these patients. Some background T2D is a condition that involves high levels of glucose (sugar) in the blood. Over time, high blood sugar can...

Read More

Can SGLT2 inhibitors improve weight and overall health in patients with diabetes?

Can SGLT2 inhibitors improve weight and overall health in patients with diabetes?

Posted by on Apr 4, 2021 in Diabetes mellitus | 0 comments

In a nutshell This review looked at how SGLT2 inhibitor medications affected the health of patients with type 2 diabetes (T2D). It found that SGLT2 inhibitors improved body weight and heart and liver health in these patients. Some background T2D is a condition in which the body does not adequately control the amount of glucose (sugar) in the blood....

Read More

A Silent Condition: Chronic Kidney Disease

A Silent Condition: Chronic Kidney Disease

Posted by on Mar 28, 2021 in Diabetes mellitus, Hypertension, Kidney stones, Stroke, Urinary tract infection |

March is National Kidney Month. People don’t think about their kidneys until something goes wrong with them. Several Medivizor blog posts have described the structures in the kidney, the connection between kidneys and blood pressure, and  kidney stones and the risk of heart attack or stroke. Chronic Kidney Disease is another kidney problem but it is...

Read More

Does empagliflozin reduce the risk of heart attack, stroke and death in patients with type 2 diabetes and heart disease?

Does empagliflozin reduce the risk of heart attack, stroke and death in patients with type 2 diabetes and heart disease?

Posted by on Mar 28, 2021 in Diabetes mellitus | 0 comments

In a nutshell This study looked at the risk of heart attack, stroke, and death in patients with type 2 diabetes (T2D) and heart disease treated with empagliflozin (Jardiance). They found that empagliflozin reduced the total risk of heart attack, stroke, or death in these patients. Some background Patients with T2D and coronary artery...

Read More

Comparing safety and effectiveness of liraglutide to insulin glargine after hospital discharge in patients with uncontrolled type 2 diabetes.

Comparing safety and effectiveness of liraglutide to insulin glargine after hospital discharge in patients with uncontrolled type 2 diabetes.

Posted by on Mar 28, 2021 in Diabetes mellitus | 0 comments

In a nutshell This study compared the safety and effectiveness of liraglutide (Victoza) to insulin glargine (Lantus) on glycemic (blood glucose) control in patients with type 2 diabetes (T2D) after hospital discharge. The authors concluded that liraglutide treatment led to improved glycemic control and greater weight loss compared to...

Read More

Is omarigliptin safe and effective in insulin-treated patients with uncontrolled type 2 diabetes?

Is omarigliptin safe and effective in insulin-treated patients with uncontrolled type 2 diabetes?

Posted by on Feb 28, 2021 in Diabetes mellitus | 0 comments

In a nutshell This study looked at the use of omarigliptin (Marizev) in insulin-treated patients with uncontrolled type 2 diabetes (T2D). It found that omarigliptin was well-tolerated and improved blood glucose control.  Some background Type 2 diabetes (T2D) is usually treated initially with diet, exercise, and...

Read More

Reduced risk of heart failure hospitalizations in patients with type 2 diabetes using SGLT-2 inhibitors

Reduced risk of heart failure hospitalizations in patients with type 2 diabetes using SGLT-2 inhibitors

Posted by on Feb 28, 2021 in Diabetes mellitus | 0 comments

In a nutshell This review focused on the effect of sodium-glucose cotransporter-2 inhibitors (SGLT-2i) on heart failure hospitalization in patients with type 2 diabetes (T2D). This analysis showed that SGLT-2is may reduce the risk of heart failure hospitalizations in these patients. Some background Patients with T2D have a higher risk of developing...

Read More